Testicular Cancer Drugs Market: Global Industry Analysis 2023

Testicular cancer is observed in males aged between 15 to 44 years where major symptoms include forming a painless lump or swelling in testicles. If the cancer is left untreated, the eventual course is metastasis and mortality. However, due to advances in multimodal treatments which include surgery, radiation and chemotherapy, a cure for this type of cancer is commonly achieved. Testicular cancer is classified into different types of cancer depending on the type cell in which cancer begins. Cancer developed in germ cells is termed as germ cell testicular cancer and is the most common type. Germ cell testicular cancers account for more than 95% of all testicular cancer cases and are further segmented into seminomas and non-seminomas which approximately account for 40% and 60% of total germ cell testicular cancer. The other less prevalent types of testicular cancers include include Leydig cell tumors (1% to 3%) and Sertoli cell tumors (less than 1%). The treatment of testicular cancer is determined on the type of cancer and the level of advancement of tumor within the body.

Download The Full Brouchre of Report: https://goo.gl/Ng6DI1

Testicular cancer itself is a relatively uncommon and accounts for less than 1 percent of all types of cancer incidences. Globally the cancer is more prevalent in the developed regions which include Australia, North America and Europe. In 2011, approximately 2,207 men in the U.K. were diagnosed with testicular cancer while 68 men died from this disease. The American Cancer Society estimates that in 2014 about 8,820 new cases of testicular cancer will be diagnosed and 380 deaths will occur in the U.S. The rate of incidences of testicular cancer has been observed to be rising every year across the world, however the curability of this disease has increased the survival rate of patients affecting with it. For instance, only four percent of testicular cancer patients in the U.S. die within first five years of getting the disease. Hence, more people are getting treated each year with this type of cancer which reflects the growth of the global testicular cancer drugs market.

The global testicular cancer drugs market is classified on the basis of cancer types into three segments, namely germ cell cancer drugs market, Leydig cell cancer drugs market and Sertoli cell cancers market. The main drugs used in treating testicular cancer are cisplatin, etoposide, ifosfamide, paclitaxel, and vinblastine. Other drugs used for treating testicular cancer include bleomycin, dactinomycin. The treatment is more effective if the chemotherapy regimen involve 2 or more drugs rather than using any single drug. The common chemotherapy regimens for treatment of testicular cancer are BEP (bleomycin, etoposide, and cisplatin), EP (etoposide and cisplatin), TIP (paclitaxel, ifosfamide, and cisplatin), and VIP (VP-16/etoposide or vinblastin, ifosfamide and cisplatin). Some of these drugs can have serious side effects such as kidney damage, lung damage, neuropathy, and hemorrhagic cystitis and therefore have to be administered with utmost care and monitoring the effects of these drugs. However, the side effects last shortly and do not affect the patient permanently unless the dosage regimens include very high doses for ling duration.

Some of the key players in the global testicular cancer drugs market include Bristol-Myers Squibb Co., Hospira Inc., Ovation Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., ZIOPHARM Oncology Inc., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.

Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/testicular-cancer-drugs-market.html

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of

Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.